Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Search


Fresh Filings
May 31, 2025
Notable recent court filings in entertainment law.
Real Property Law
May 31, 2025
Mutual Mistake About Ownership Does Not Defeat Cotenant’s Adverse Possession Claim; Servient Owner’s Laches Defense Reinstated In Easement Dispute; Constructive Notice Precludes Village’s Claim to Be Free of State’s Unrecorded Easement; Complaint Does Not Support Claim That Deed Was Forged
Law Firm Leasing Boomed During Q1 of 2025
May 31, 2025
Law firm leasing boomed during the first quarter of 2025, with double the volume during the same period of 2024, and 68.8% of firms chose to stay in place, a significant increase from recent years.
Managing Consumer Data In Bankruptcy Proceedings
May 31, 2025
Consumer genetics company 23andMe’s bankruptcy in late March set off a scramble among consumers to delete their personal information held by the company, driven by fears of how an acquiring party might attempt to use or monetize their data.
DOJ Shifts White-Collar Crime Enforcement Strategies
May 31, 2025
The DOJ announced on May 12, 2025, a strategy shift in its approach to white collar enforcement, identifying specific high-impact areas of focus; an expansion of whistleblower and self-disclosure incentives; and a narrowed use of corporate monitorships. These strategic shifts present significant opportunities for companies and individuals currently facing government investigations, particularly where those investigations no longer align with DOJ priorities.
Players On the Move
May 31, 2025
A look at moves among attorneys, law firms, companies and other players in entertainment law.
FDIC Report Tells Concerning Story for CRE
May 31, 2025
The latest quarterly report from the Federal Deposit Insurance Corporation underscores mounting pressure in the commercial real estate sector, signaling potential headwinds for the industry.
Third Circuit Reinstates Sanctions Against Law Firm for Failing to Fully Disclose Its Fees In A Chapter 7 Bankruptcy
May 31, 2025
The U.S. Court of Appeals for the Third Circuit has reinstated sanctions against Spector Gadon Rosen & Vinci for failing to fully disclose its fees in a Chapter 7 bankruptcy.
AI and the Billable Hour: Transactional Work First to See Changes
May 31, 2025
The end of the billable hour has been prophesied for years. But, as the steady adoption of artificial intelligence upends how legal work gets done, the promised efficiencies from automation are most likely to emerge in certain elements of deal work, like due diligence and contract review and analysis.
Co-ops and Condominiums
May 31, 2025
Co-Op Entitled to Withhold Consent to Sublet; Unit Owner Lacks Standing to Challenge Another Owner’s Parking Practices; Fair Housing Act Challenge Dismissed

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›